DE60119285D1 - Verwendung von plgf zur vorbeugung oder behandlung von ischaemie oder schlaganfall - Google Patents

Verwendung von plgf zur vorbeugung oder behandlung von ischaemie oder schlaganfall

Info

Publication number
DE60119285D1
DE60119285D1 DE60119285T DE60119285T DE60119285D1 DE 60119285 D1 DE60119285 D1 DE 60119285D1 DE 60119285 T DE60119285 T DE 60119285T DE 60119285 T DE60119285 T DE 60119285T DE 60119285 D1 DE60119285 D1 DE 60119285D1
Authority
DE
Germany
Prior art keywords
ischaemie
plgf
hitch
treat
prevent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60119285T
Other languages
English (en)
Other versions
DE60119285T2 (de
Inventor
Peter Carmeliet
Desire Collen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FLANDERS INTERUNIVERSITY INST
Vlaams Instituut voor Biotechnologie VIB
Desire Collen Research Foundation vzw
Original Assignee
FLANDERS INTERUNIVERSITY INST
Vlaams Instituut voor Biotechnologie VIB
Desire Collen Research Foundation vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0002527A external-priority patent/GB0002527D0/en
Application filed by FLANDERS INTERUNIVERSITY INST, Vlaams Instituut voor Biotechnologie VIB, Desire Collen Research Foundation vzw filed Critical FLANDERS INTERUNIVERSITY INST
Publication of DE60119285D1 publication Critical patent/DE60119285D1/de
Application granted granted Critical
Publication of DE60119285T2 publication Critical patent/DE60119285T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Vascular Medicine (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pressure Vessels And Lids Thereof (AREA)
  • Dowels (AREA)
  • Clamps And Clips (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
DE60119285T 2000-02-04 2001-02-05 Verwendung von plgf zur vorbeugung oder behandlung von ischaemie oder schlaganfall Expired - Lifetime DE60119285T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0002527 2000-02-04
GB0002527A GB0002527D0 (en) 2000-02-04 2000-02-04 Use of vascular endothelial growth factor (VEGF) placental growth factor (PLGF)or both for the treatment of ischemic and acute myocardial infaction
US23659400P 2000-09-29 2000-09-29
US236594P 2000-09-29
PCT/EP2001/001208 WO2001056593A2 (en) 2000-02-04 2001-02-05 Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke

Publications (2)

Publication Number Publication Date
DE60119285D1 true DE60119285D1 (de) 2006-06-08
DE60119285T2 DE60119285T2 (de) 2007-05-10

Family

ID=26243563

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60119285T Expired - Lifetime DE60119285T2 (de) 2000-02-04 2001-02-05 Verwendung von plgf zur vorbeugung oder behandlung von ischaemie oder schlaganfall

Country Status (9)

Country Link
EP (1) EP1253935B1 (de)
JP (1) JP4969753B2 (de)
AT (1) ATE324905T1 (de)
AU (2) AU4643501A (de)
DE (1) DE60119285T2 (de)
DK (1) DK1253935T3 (de)
ES (1) ES2263582T3 (de)
PT (1) PT1253935E (de)
WO (2) WO2001057181A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2405291A1 (en) * 2000-04-06 2001-10-18 Wayne P. Franco Methods of using growth factors for treating heart disease
CA2454251A1 (en) * 2001-08-10 2003-02-20 Imclone Systems Incorporated Isolation and mobilization of stem cells expressing vegfr-1
ITRM20020119A1 (it) 2002-03-05 2003-09-05 Geymonat Spa Composizioni contenenti plgf ad uso farmaceutico e cosmetico.
US8409815B2 (en) 2002-11-16 2013-04-02 Siemens Healthcare Diagnostics Products Gmbh sCD40L and placental growth factor (PLGF) used as a biochemical marker combination in cardiovascular diseases
EP2295449A1 (de) 2009-09-09 2011-03-16 Dompe PHA.R.MA S.p.A. PLGF-1 in homodimerer Form
EP3586867A3 (de) * 2013-01-28 2020-04-08 Shire Human Genetic Therapies, Inc. Plazentawachstumsfaktor bei der behandlung von duchenne-muskeldystrophie

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
DK0956339T3 (da) * 1996-08-23 2006-01-30 Licentia Oy Rekombinant vaskulær endotelcellevækstfaktor D (VEGF-D)
AU7250298A (en) * 1997-04-25 1998-11-24 Collateral Therapeutics, Inc. Truncated vegf-related proteins
GB2332373A (en) * 1997-12-19 1999-06-23 Merck & Co Inc Treatment of coronary and/or peripheral ischemia using an antithrombotic agent and an angiogenesis promoter
SG117417A1 (en) * 1998-02-06 2005-12-29 Collateral Therpeutics Inc Variants of the angiogenic factor vascular endothelial cell growth factor: vegf

Also Published As

Publication number Publication date
WO2001056593A2 (en) 2001-08-09
EP1253935B1 (de) 2006-05-03
DE60119285T2 (de) 2007-05-10
DK1253935T3 (da) 2006-09-04
AU2001230243A1 (en) 2001-08-14
JP4969753B2 (ja) 2012-07-04
ATE324905T1 (de) 2006-06-15
AU4643501A (en) 2001-08-14
EP1253935A2 (de) 2002-11-06
JP2003521522A (ja) 2003-07-15
PT1253935E (pt) 2006-08-31
WO2001056593A3 (en) 2002-04-25
ES2263582T3 (es) 2006-12-16
WO2001057181A2 (en) 2001-08-09

Similar Documents

Publication Publication Date Title
ATE489957T1 (de) Mittel zur behandlung von entzündlichen erkrankungen
ATE303156T1 (de) Verwendung von gnrh-analogue zur behandlung der harninkontinenz
MEP8209A (en) Modified factor viii
AR023130A1 (es) Composiciones para promover el crecimiento
ATE468137T1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
DE69925024D1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
EA200400482A1 (ru) Кератиноциты, пригодные для применения в качестве биологически активной субстанции при лечении ран
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
ATE254461T1 (de) Behandlung von augenschmerzen
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
HK1205531A1 (en) Mesenchymal stem cells and uses therefor
DE60206289D1 (de) Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne
ATE418552T1 (de) Substituierte amino-furan-2-yl-essigsaure- und amino-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DE60119285D1 (de) Verwendung von plgf zur vorbeugung oder behandlung von ischaemie oder schlaganfall
TR200200278T2 (tr) Kalsilitik bileşimler
DE69818809D1 (de) Verfahren zur behandlung von narbengewebe
DE602004019541D1 (de) Cycloalkyläbü kondensierte indole
DE60209886D1 (de) Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
ATE300944T1 (de) Verwendung von substituierten distamycin- acryloylderivaten zur behandlung von tumoren die mit erhöhten glutathion-spiegeln zusammenhängen
ATE236633T1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
ATE291425T1 (de) R-eliprodil zur behandlung von glaucoma
ATE222501T1 (de) Tissue-faktor zur beeinflussung von gefässbildung
ATE343387T1 (de) S-methyl-dihydro-ziprasidon zur behandlung von augenerkrankungen.
DE60128084D1 (de) Verwendung von inaktives cln2 proenzym zur behandlung von lincl
DE60137506D1 (de) Verwendung von polysulfatierten cyclodextrinen zur behandlung von arthrose

Legal Events

Date Code Title Description
8364 No opposition during term of opposition